-
公开(公告)号：US20240175010A1
公开(公告)日：2024-05-30
申请号：US18476486
申请日：2023-09-28
Applicant: Illumina, Inc.
Inventor： Allison Yunghans , Angelica Marie Barr Schalembier , Kayla Busby , Stephen M. Gross
IPC: C12N15/10 , C12N9/00 , C12N9/22 , C12N9/24 , C12Q1/6874
CPC classification number: C12N15/1082 , C12N9/22 , C12N9/2497 , C12N9/93 , C12N15/1096 , C12Q1/6874 , C12Y302/0202 , C12Y302/02023 , C12Y302/02027 , C12Y302/02029 , C12Y605/01001
Abstract: Disclosed herein is a modified transposon end sequence comprising a mosaic end sequence, wherein the mosaic end sequence comprises one or more mutation as compared to a wild-type mosaic end sequence, wherein the mutation comprises a substitution with a uracil, an inosine, a ribose, an 8-oxoguanine, a thymine glycol, a modified purine, or a modified pyrimidine. Also disclosed are transposome complexes comprising these modified transposon end sequences and methods of library preparation using these modified transposon end sequences.
-
公开(公告)号：US20170202915A1
公开(公告)日：2017-07-20
申请号：US15389509
申请日：2016-12-23
Applicant: TUFTS UNIVERSITY
Inventor： Noorjahan Panjwani , Wei-Sheng Chen
CPC classification number: A61K38/1732 , A61K31/702 , A61K38/47 , C12Y302/02029 , G01N33/6893 , G01N2333/4724 , G01N2333/912 , G01N2800/52
Abstract: Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection.
-
3.发明申请COMBINATION OF DNA REPAIR INHIBITION WITH BENDAMUSTINE OR GEMCITABINE IN THE TREATMENT OF CANCER 审中-公开DNA修复与BENDAMUSTINE或GEMCITABINE在治疗癌症中的组合
公开(公告)号：US20150164934A1
公开(公告)日：2015-06-18
申请号：US14540428
申请日：2014-11-13
Inventor： ALFONSO BELLACOSA , TIMOTHY YEN , NEIL BEEHARRY , MITCHELL SMITH , ROSSELLA TRICARICO , VIKRAM BHATTACHARJEE , PIETRO MANCUSO
IPC: A61K31/7068 , A61K31/277 , A61K31/546 , A61K31/4184 , A61K31/122
CPC classification number: A61K31/7068 , A61K31/122 , A61K31/277 , A61K31/4184 , A61K31/546 , A61K31/7088 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12Y302/02029 , A61K2300/00
Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
Abstract translation: 本发明提供了增强表达胸腺嘧啶DNA糖基化酶的癌细胞中DNA损伤的细胞毒性的方法，并相应地治疗肿瘤。 所述方法包括抑制胸腺嘧啶DNA糖基化酶的表达或生物活性，并诱导癌细胞中的DNA损伤。 DNA损伤可以通过给予癌细胞给予苯达莫司汀或吉西他滨诱导。
-
4.发明授权Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer 有权组合DNA修复抑制与苯达莫司汀或吉西他滨治疗癌症
公开(公告)号：US08927516B2
公开(公告)日：2015-01-06
申请号：US13836414
申请日：2013-03-15
Applicant: Institute for Cancer Research
Inventor： Alfonso Bellacosa , Timothy Yen , Neil Beeharry , Mitchell Smith
IPC: C12N15/113 , A61K31/4184 , A61K31/7068 , A61K31/7088
CPC classification number: C12N15/1137 , A61K31/4184 , A61K31/7068 , A61K31/7088 , C12N2310/14 , C12N2320/31 , C12Y302/02029 , A61K2300/00
Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
Abstract translation: 本发明提供了增强表达胸腺嘧啶DNA糖基化酶的癌细胞中DNA损伤的细胞毒性的方法，并相应地治疗肿瘤。 所述方法包括抑制胸腺嘧啶DNA糖基化酶的表达或生物活性，并诱导癌细胞中的DNA损伤。 DNA损伤可以通过给予癌细胞给予苯达莫司汀或吉西他滨诱导。
-
5.发明申请
公开(公告)号：US20130303588A1
公开(公告)日：2013-11-14
申请号：US13836414
申请日：2013-03-15
Inventor： Alfonso Bellacosa , Timothy Yen , Neil Beeharry , Mitchell Smith
IPC: C12N15/113
CPC classification number: C12N15/1137 , A61K31/4184 , A61K31/7068 , A61K31/7088 , C12N2310/14 , C12N2320/31 , C12Y302/02029 , A61K2300/00
Abstract: The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.
